Philips partners with Nuvo Group for remote pregnancy monitoring and more digital health briefs

med tech large Royal Philips is partnering with Nuvo Group to assist remote pregnancy monitoring in rural areas.

The collaboration will begin with a pilot program in rural Colorado utilizing Nuvo’s INVU remote monitoring system, which was cleared by the FDA final yr. The firms say this system may enhance entry to maternity care in rural communities, the place a lack of options contributes to worse outcomes and increased mortality charges.

“Digital solutions and ecosystem-building are critical enablers to addressing disparities in healthcare such as access to maternal health care in rural settings,” Sandra Lesenfants, basic supervisor, hospital affected person monitoring, at Philips, mentioned in an announcement. “With this collaboration, we are extending the sight and reach of pregnancy care and bringing more remote monitoring options to the communities and expectant mothers where and when they need them most.”

Prescription digital therapeutics firm Pear Therapeutics will now be obtainable in Epic’s App Orchard Gallery, permitting suppliers to observe sufferers utilizing the corporate’s therapeutics inside the EHR.

Including the PearJoin service platform within the gallery will enhance workflows for suppliers as they handle sufferers utilizing reSET or reSET-O for substance use and opioid use problems, the corporate mentioned. They’ll be capable of overview affected person progress and doc remote monitoring work for reimbursement.

“We are excited to bring this opportunity to expand access to our PDTs, with the initial listing of our PearConnect platform in the App Orchard gallery to support reSET and reSET-O patients. We believe Pears integration with Epic will create a pathway for healthcare providers to easily access our PearConnect platform and enable scale to serve many more patients,” Pear chief industrial officer Julia Strandberg mentioned in an announcement.

Virtual actuality therapeutics startup AppliedVR introduced it has modified the identify of its EaseVRx therapeutic to RelieVRx.

The system acquired FDA De Novo clearance to deal with persistent decrease again ache in November. AppliedVR plans to launch the rebranded RelieVRx in a number of markets this yr to organize for its full launch in 2023.

“While ease of use is definitely an important part of our design, ultimately we wanted a name that better reflected how our innovative product intends to provide life-changing relief. With demonstrated efficacy data, ‘RelieVRx’ better captures the core benefit of pain relief that the healthcare industry is looking for: a prescription treatment option that provides a unique modality while addressing unmet patient needs,” cofounder and CEO Matthew Stoudt mentioned in an announcement.

The firm additionally introduced it had appointed Dr. Charisse Y. Sparks as chief medical officer to assist the RelieVRx launch and its potential growth for different medical wants. Sparks most not too long ago labored at DePuySynthes, the orthopedic system arm of Johnson & Johnson.

“Racial, ethnic and economic disparities in chronic pain management are well established. Reliable studies show that these disparities show up in the undertreatment of pain as well as overdose deaths, which continue to increase,” Sparks mentioned in an announcement. “I am looking forward to making immersive therapeutics a standard of care in chronic pain management and establishing AppliedVR as a leader in health equity for the digital health industry.”


Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button